Inventor
DOUGLAS L. SHERIDAN
Inventor
US
Overview
Patents· 8 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
C07KPeptides30%
A61KPreparations for medical, dental or toiletry purposes26%
C12YEnzymes7%
G01NInvestigating or analysing materials by determining their chemical or physical properties4%
Y02ATechnologies for adaptation to climate change4%
PatentTitleYear
12,497,445Monovalent anti-properdin antibodies and antibody fragments202512,240,893Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)202512,221,473Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof202511,802,154Humanized anti-CD200 antibodies and uses thereof202311,498,960Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof202211,434,280Anti-C5 antibodies having improved pharmacokinetics202211,407,821Anti-C5A antibodies202211,198,725Monovalent anti-properdin antibodies and antibody fragments2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2025Patents assigned to ALEXION PHARMA INC (8)· patent assignee history
2021–2025Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| ALEXION PHARMA INC | 8 | 2021–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 8 | 2021–2025 |